China National Biotec Group (CNBG), a wholly-owned affiliate of Chinese healthcare group Sinopharm, is picking up a stake in US-based aesthetic gel implant technology developer Advanced Aesthetic Technologies (AAT) to serve the largely unmet medical aesthetics market in China.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
